On September 23, 2021, the “Ernst & Young and Fudan Most Promising Enterprises in 2021 Award Ceremony & High-Growth Company Forum” was held in Shanghai, which announced 25 companies with the greatest potential in  seven major fields including advanced manufacturing, strategic emerging industry, future oriented industry, modern services, emerging services , infrastructure and digital economy. Standing out from numerous companies included in the appraisal, NeoCura Bio-Medical Technology Co., Ltd. won the title of “Ernst & Young and Fudan Most Promising  Enterprise 2021”!

Dr. Wang Yi, Founder & CEO of NeoCura, said in her acceptance speech that, “We are sincerely grateful for this honor to NeoCura. To us, it is not only an affirmation but also an impetus. Ever since its establishment, NeoCura has been focusing on the research of RNA innovative drugs. We want to advance the research and development of innovative RNA drugs through AI and bioinformatic technologies, so that more cancer patients can benefit from such emerging treatment regimens to improve their quality of life and prolong their survival, thereby bringing hope to cancer patients.”

In 2021, China's economic and social development has entered the fourteenth five-year period. On this extremely challenging road, many outstanding Chinese companies have brought new perspectives to the market. The “Ernst & Young and Fudan Most Promising Enterprises 2021” appraisal activity lasted 5 months. The panel of judges focused on companies’ comprehensive strength  in terms of “promising future growth and sustainable development”, “national and international development”, and “unequivocal competitive advantages” and eventually identified 25 companies with the greatest comprehensive strength. It aims to seek future industry leaders that are swimming against the stream, disrupting traditional technologies, and exploring new market space.

In this year’s appraisal, new-generation artificial intelligence and genetic & biological technologies have been selected as the two major directions of future industries in China. As an AI-enabled RNA drug  company, NeoCura has become a leader in the industry and stood out from the crowd. With the debut of SARS-CoV-2 mRNA vaccines under global spotlight, mRNA technology has accelerated its breakthrough development. NeoCura,featuring RNA drug research and development, has also entered fast track, making itself a focus of attention in the industry and capital market.

NeoCura is committed to building  global leading RNA innovative drug platform. It has built multi-omics big data collection platform and multi-biomics database, carried out deep drug target mining and fully automated drug design based on AI and bioinformatic technologies for innovative RNA drug development, and has made strategic deployment in multiple directions such as cancer neoantigen vaccines and tumor microenvironment immunomodulators. In the future, NeoCura will expedite the IND submission of RNA drug pipelines, enrich  real-world data on cancer neoantigen,  further explore tumor immunotherapy clinical protocols, and contribute to the technical breakthrough of global RNA pharmaceutical industry and the clinical application of tumor immunotherapy.